查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028052

孤兒藥市場規模、佔有率、成長率及全球市場分析：按類型、應用和地區分類，並預測至2026-2034年

Orphan Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

孤兒藥市場成長要素

受罕見疾病認知度提高和監管力度加大的推動，全球孤兒藥市場正經歷強勁成長。預計該市場規模在2025年將達到2,102.6億美元，2026年將成長至2,341.7億美元，到2034年將達到6,038.9億美元，2026年至2034年的複合年成長率（CAGR）為12.57%。

由於先進的醫療基礎設施、優惠的報銷政策和強大的研發投入，預計到 2025 年，北美將以 54.04% 的市場佔有率主導全球市場。僅美國市場，在政府激勵措施（例如稅額扣抵和孤兒藥市場獨佔權）的支持下，預計到 2032 年將達到 2,373.9 億美元。

市場趨勢

影響孤兒藥市場的關鍵趨勢之一是針對罕見疾病的創新產品不斷出現。製藥公司正加大對標靶治療的投資，例如生物製藥和基因療法。

此外，重磅孤兒藥正吸引人們的注意。根據業內人士估計，到2026年，主要孤兒藥的銷售額將達到數十億美元。精準醫療和免疫療法的日益普及也正在改變罕見疾病的治療模式。

市場成長要素

1. 增加研發投資

加大研發投入是市場成長的主要驅動力。製藥公司正致力於開發新治療方法，因為治療罕見疾病具有很高的成功潛力。

政府措施也在促進創新。例如，鼓勵醫藥領域（尤其是在新興市場）研發和創新的政策，正在加速藥物開發平臺。

2. 罕見病患疾病率增加

全球罕見疾病患者人數的增加顯著推高了對孤兒藥的需求。據估計，全球約有3億人患有罕見疾病，其中數百萬人缺乏有效的治療方法。

患者群體的擴大促使各公司投資於先進治療方法並擴大產品系列。

3. 有利的監管支持

孤兒藥認定、加速核准和財政獎勵等支持性框架正在推動企業開發罕見疾病療法。這些政策降低了研發風險，並提高了盈利。

市場限制因素

儘管市場成長潛力大，但由於孤兒藥高成本，市場面臨許多挑戰。某些治療方法的單劑費用高達數百萬美元，這限制了患者獲得治療的機會，尤其是在開發中國家。

此外，保險覆蓋範圍有限且自付費用高昂阻礙了治療的廣泛普及，進而影響了整體市場成長。

細分分析

按治療區域

  • 到 2026 年，腫瘤領域將主導市場，佔 47.42% 的佔有率，這主要得益於癌症相關孤兒藥核准的增加。
  • 血液學和神經病學領域也透過不斷創新和臨床進步而不斷發展壯大。
  • 預計對免疫調節療法的需求不斷成長將推動免疫療法領域的強勁成長。

依藥物類型

  • 生物製藥在治療複雜的罕見疾病方面非常有效，並將佔最大的市場佔有率（到 2026 年將達到 74.44%）。
  • 儘管非生物製藥的市場佔有率較小，但它們作為一種治療選擇仍然發揮著重要作用。

透過分銷管道

  • 由於許多治療需要臨床監督，預計到 2026 年，醫院藥局將引領市場，佔 46.42% 的市場佔有率。
  • 由於便利性和數位化技術的進步，網路藥局正在迅速崛起。

區域趨勢

北美洲

北美市場處於領先地位，預計2025年市場規模將達到1,136.4億美元，2026年將達1,266.7億美元。這一主導地位歸功於強大的研發能力和較高的疾病認知水平。

歐洲

預計到 2025 年，歐洲的市場規模將達到 539.4 億美元，在監管措施和龐大患者群體的支持下，預計到 2026 年將達到 599.3 億美元。

亞太地區

該地區正在快速成長，2025 年市場規模將達到 357.6 億美元，預計到 2026 年將達到 400.8 億美元，這主要得益於醫療保健支出的增加和人們對疾病認知的提高。

世界其他地區

在拉丁美洲、中東和非洲等地區，由於醫療保健服務的改善，市場成長較為溫和，但市場滲透率仍然很低。

大公司

孤兒藥市場的主要參與者包括以下公司：

  • Amgen Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Novo Nordisk A/S

這些公司正專注於策略聯盟、收購和拓展產品線，以鞏固其市場地位。

產業趨勢

近期趨勢包括透過合作、收購和監管核准等方式加速藥物研發。各公司正日益加強合作，以更快地將創新治療方法推向市場，並改善全球患者的用藥途徑。

然而，治療費用高昂仍然是一個重大挑戰，需要解決以確保更廣泛的患者群體能夠獲得治療。總體而言，隨著持續的創新和監管支持，預計該市場將在全球罕見疾病治療領域發揮關鍵作用。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家及地區罕見病患疾病率
  • 大型公司管道分析
  • 新產品發布
  • 產業重大發展：合併、收購與合作。
  • 技術發展
  • 新冠疫情的影響：全球孤兒藥市場

第5章：2021-2034年全球孤兒藥市場分析、洞察與預測

  • 市場分析、洞察與預測：按治療領域分類
    • 腫瘤學
    • 血液學
    • 神經病學
    • 內分泌學
    • 心血管系統
    • 呼吸系統
    • 免疫療法
    • 感染疾病
    • 其他
  • 市場分析、洞察與預測：按藥物類型分類
    • 生物製藥
    • 非生物製藥
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美孤兒藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲孤兒藥市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區孤兒藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：2021-2034年世界其他地區孤兒藥市場分析、洞察與預測

第10章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Amgen Inc.（US）
    • Bayer AG（Germany）
    • F. Hoffmann-La Roche Ltd（Switzerland）
    • Alexion Pharmaceuticals Inc.（US）
    • Novo Nordisk A/S（Denmark）
    • Novartis AG（Switzerland）
    • Bristol-Myers Squibb Company（US）
    • AstraZeneca（UK）
    • DAIICHI SANKYO COMPANY, LIMITED（Japan）
    • GlaxoSmithKline plc（UK）
Product Code: FBI100088

Growth Factors of orphan drugs Market

The global orphan drugs market is witnessing robust growth due to increasing awareness of rare diseases and strong regulatory support. The market was valued at USD 210.26 billion in 2025 and is projected to grow to USD 234.17 billion in 2026, reaching USD 603.89 billion by 2034, registering a CAGR of 12.57% during 2026-2034.

North America dominated the global market with a 54.04% share in 2025, driven by advanced healthcare infrastructure, favorable reimbursement policies, and strong research investments. The U.S. market alone is expected to reach USD 237.39 billion by 2032, supported by government incentives such as tax credits and market exclusivity for orphan drugs.

Market Trends

One of the key trends shaping the orphan drugs market is the rise in innovative product launches targeting rare diseases. Pharmaceutical companies are increasingly investing in targeted therapies such as biologics and gene therapies.

Additionally, blockbuster orphan drugs are gaining prominence. According to industry estimates, the top orphan drugs are expected to generate multi-billion-dollar revenues by 2026. The growing focus on precision medicine and immunotherapies is also transforming the treatment landscape for rare diseases.

Market Growth Drivers

1. Increasing R&D Investments

The rising investment in research and development is a major factor driving market growth. Pharmaceutical companies are focusing on developing novel therapies due to the high success potential in rare disease treatments.

Government initiatives are also supporting innovation. For example, policies promoting pharmaceutical R&D and innovation, especially in emerging markets, are accelerating drug development pipelines.

2. Growing Prevalence of Rare Diseases

The increasing number of rare disease patients globally is significantly boosting demand for orphan drugs. It is estimated that 300 million people worldwide are affected by rare diseases, with millions lacking effective treatment options.

This growing patient pool is encouraging companies to invest in advanced therapies and expand their product portfolios.

3. Favorable Regulatory Support

Supportive frameworks such as orphan drug designation, fast-track approvals, and financial incentives are encouraging companies to develop rare disease treatments. These policies reduce development risks and improve profitability.

Market Restraints

Despite strong growth potential, the market faces challenges due to the high cost of orphan drugs. Some therapies cost millions per treatment, limiting accessibility, especially in developing countries.

Additionally, limited reimbursement coverage and high out-of-pocket expenses restrict adoption, thereby impacting overall market growth.

Segmentation Analysis

By Therapy Area

  • Oncology dominates the market with a 47.42% share in 2026, driven by increasing cancer-related orphan drug approvals.
  • Hematology and neurology segments are also growing due to ongoing innovations and clinical advancements.
  • Immunotherapy is expected to witness strong growth due to rising demand for immune-modulating treatments.

By Drug Type

  • Biologics hold the largest share (74.44% in 2026) due to their effectiveness in treating complex rare diseases.
  • Non-biologics account for a smaller share but continue to play a role in treatment options.

By Distribution Channel

  • Hospital pharmacies dominate with 46.42% share in 2026, as many treatments require clinical supervision.
  • Online pharmacies are emerging rapidly due to convenience and increased digital adoption.

Regional Insights

North America

North America leads the market, valued at USD 113.64 billion in 2025 and projected to reach USD 126.67 billion in 2026. The dominance is attributed to strong R&D capabilities and high disease awareness.

Europe

Europe accounted for USD 53.94 billion in 2025 and is expected to reach USD 59.93 billion in 2026, supported by regulatory initiatives and a large patient population.

Asia Pacific

The region is growing rapidly, with a market size of USD 35.76 billion in 2025, rising to USD 40.08 billion in 2026, driven by increasing healthcare spending and awareness.

Rest of the World

Regions such as Latin America and the Middle East & Africa are witnessing gradual growth due to improving healthcare access but remain underpenetrated.

Key Companies

Major players in the orphan drugs market include:

  • Amgen Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Novo Nordisk A/S

These companies focus on strategic collaborations, acquisitions, and pipeline expansion to strengthen their market position.

Industry Developments

Recent developments include partnerships, acquisitions, and regulatory approvals aimed at accelerating drug development. Companies are increasingly collaborating to bring innovative therapies to market faster and improve patient access globally.

Conclusion

The orphan drugs market is set for significant long-term growth, expanding from USD 210.26 billion in 2025 to USD 603.89 billion by 2034. Strong R&D investments, supportive government policies, and a growing rare disease population are key growth drivers.

However, high treatment costs remain a critical challenge that needs to be addressed to ensure wider accessibility. Overall, with continuous innovation and regulatory support, the market is expected to play a crucial role in transforming rare disease treatment worldwide.

Segmentation By Therapy Type

  • Oncology
  • Hematology
  • Neurology
  • Endocrinology
  • Cardiovascular
  • Respiratory
  • Immunotherapy
  • Infectious Diseases
  • Others

By Drug Type

  • Biologics
  • Non-biologics

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America (By Therapy Type, By Drug Type, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of the World (By Therapy Type, By Drug Type, By Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Rare Diseases, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches
  • 4.4. Key Industry Developments: Mergers, Acquisitions & Partnerships
  • 4.5. Technological Developments
  • 4.6. Impact of COVID-19 on the Global Orphan Drugs Market

5. Global Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 5.1.1. Oncology
    • 5.1.2. Hematology
    • 5.1.3. Neurology
    • 5.1.4. Endocrinology
    • 5.1.5. Cardiovascular
    • 5.1.6. Respiratory
    • 5.1.7. Immunotherapy
    • 5.1.8. Infectious Diseases
    • 5.1.9. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Type
    • 5.2.1. Biologics
    • 5.2.2. Non-Biologics
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Online Pharmacies
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 6.1.1. Oncology
    • 6.1.2. Hematology
    • 6.1.3. Neurology
    • 6.1.4. Endocrinology
    • 6.1.5. Cardiovascular
    • 6.1.6. Respiratory
    • 6.1.7. Immunotherapy
    • 6.1.8. Infectious Diseases
    • 6.1.9. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Type
    • 6.2.1. Biologics
    • 6.2.2. Non-Biologics
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 7.1.1. Oncology
    • 7.1.2. Hematology
    • 7.1.3. Neurology
    • 7.1.4. Endocrinology
    • 7.1.5. Cardiovascular
    • 7.1.6. Respiratory
    • 7.1.7. Immunotherapy
    • 7.1.8. Infectious Diseases
    • 7.1.9. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Type
    • 7.2.1. Biologics
    • 7.2.2. Non-Biologics
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 8.1.1. Oncology
    • 8.1.2. Hematology
    • 8.1.3. Neurology
    • 8.1.4. Endocrinology
    • 8.1.5. Cardiovascular
    • 8.1.6. Respiratory
    • 8.1.7. Immunotherapy
    • 8.1.8. Infectious Diseases
    • 8.1.9. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Type
    • 8.2.1. Biologics
    • 8.2.2. Non-Biologics
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 9.1.1. Oncology
    • 9.1.2. Hematology
    • 9.1.3. Neurology
    • 9.1.4. Endocrinology
    • 9.1.5. Cardiovascular
    • 9.1.6. Respiratory
    • 9.1.7. Immunotherapy
    • 9.1.8. Infectious Diseases
    • 9.1.9. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Type
    • 9.2.1. Biologics
    • 9.2.2. Non-Biologics
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Amgen Inc. (U.S.)
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & Services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Bayer AG (Germany)
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & Services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. F. Hoffmann-La Roche Ltd (Switzerland)
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & Services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Alexion Pharmaceuticals Inc. (U.S.)
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & Services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Novo Nordisk A/S (Denmark)
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & Services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Novartis AG (Switzerland)
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & Services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Bristol-Myers Squibb Company (U.S.)
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & Services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. AstraZeneca (U.K.)
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & Services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. DAIICHI SANKYO COMPANY, LIMITED (Japan)
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & Services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. GlaxoSmithKline plc (U.K.)
      • 10.2.10.1. Overview
      • 10.2.10.2. Products & Services
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Orphan Drugs Market Revenue (USD billion) Forecast, By Therapy Area, 2021-2034
  • Table 2: Global Orphan Drugs Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 3: Global Orphan Drugs Market Revenue (USD billion) Forecast, By Distribution Channels, 2021-2034
  • Table 4: Global Orphan Drugs Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 5: North America Orphan Drugs Market Revenue (USD billion) Forecast, By Therapy Area, 2021-2034
  • Table 6: North America Orphan Drugs Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 7: North America Orphan Drugs Market Revenue (USD billion) Forecast, By Distribution Channels, 2021-2034
  • Table 8: North America Orphan Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Orphan Drugs Market Revenue (USD billion) Forecast, By Therapy Area, 2021-2034
  • Table 10: Europe Orphan Drugs Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 11: Europe Orphan Drugs Market Revenue (USD billion) Forecast, By Distribution Channels, 2021-2034
  • Table 12: Europe Orphan Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Orphan Drugs Market Revenue (USD billion) Forecast, By Therapy Area, 2021-2034
  • Table 14: Asia Pacific Orphan Drugs Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 15: Asia Pacific Orphan Drugs Market Revenue (USD billion) Forecast, By Distribution Channels, 2021-2034
  • Table 16: Asia Pacific Orphan Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Orphan Drugs Market Revenue (USD billion) Forecast, By Therapy Area, 2021-2034
  • Table 18: Rest of the World Orphan Drugs Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 19: Rest of the World Orphan Drugs Market Revenue (USD billion) Forecast, By Distribution Channels, 2021-2034

List of Figures

  • Figure 1: Global Orphan Drugs Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Orphan Drugs Market Value Share (%), By Therapy Area, 2025 & 2034
  • Figure 3: Global Orphan Drugs Market Value Share (%), By Drug Type, 2025 & 2034
  • Figure 4: Global Orphan Drugs Market Value Share (%), By Distribution Channels, 2025 & 2034
  • Figure 5: Global Orphan Drugs Market Value (USD billion), By Region, 2025 & 2034
  • Figure 6: North America Orphan Drugs Market Value (USD billion), By Therapy Area, 2025 & 2034
  • Figure 7: North America Orphan Drugs Market Value Share (%), By Therapy Area, 2025
  • Figure 8: North America Orphan Drugs Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 9: North America Orphan Drugs Market Value Share (%), By Drug Type, 2025
  • Figure 10: North America Orphan Drugs Market Value (USD billion), By Distribution Channels, 2025 & 2034
  • Figure 11: North America Orphan Drugs Market Value Share (%), By Distribution Channels, 2025
  • Figure 12: North America Orphan Drugs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Orphan Drugs Market Value Share (%), By Country, 2025
  • Figure 14: Europe Orphan Drugs Market Value (USD billion), By Therapy Area, 2025 & 2034
  • Figure 15: Europe Orphan Drugs Market Value Share (%), By Therapy Area, 2025
  • Figure 16: Europe Orphan Drugs Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 17: Europe Orphan Drugs Market Value Share (%), By Drug Type, 2025
  • Figure 18: Europe Orphan Drugs Market Value (USD billion), By Distribution Channels, 2025 & 2034
  • Figure 19: Europe Orphan Drugs Market Value Share (%), By Distribution Channels, 2025
  • Figure 20: Europe Orphan Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Orphan Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Orphan Drugs Market Value (USD billion), By Therapy Area, 2025 & 2034
  • Figure 23: Asia Pacific Orphan Drugs Market Value Share (%), By Therapy Area, 2025
  • Figure 24: Asia Pacific Orphan Drugs Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 25: Asia Pacific Orphan Drugs Market Value Share (%), By Drug Type, 2025
  • Figure 26: Asia Pacific Orphan Drugs Market Value (USD billion), By Distribution Channels, 2025 & 2034
  • Figure 27: Asia Pacific Orphan Drugs Market Value Share (%), By Distribution Channels, 2025
  • Figure 28: Asia Pacific Orphan Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Orphan Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World Orphan Drugs Market Value (USD billion), By Therapy Area, 2025 & 2034
  • Figure 31: Rest of the World Orphan Drugs Market Value Share (%), By Therapy Area, 2025
  • Figure 32: Rest of the World Orphan Drugs Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 33: Rest of the World Orphan Drugs Market Value Share (%), By Drug Type, 2025
  • Figure 34: Rest of the World Orphan Drugs Market Value (USD billion), By Distribution Channels, 2025 & 2034
  • Figure 35: Rest of the World Orphan Drugs Market Value Share (%), By Distribution Channels, 2025
  • Figure 36: Global Orphan Drugs Market Share (%), By Company, 2025